
EMA’s 2025 annual report shows strong approval numbers for human and veterinary medicines
EMA’s 2025 annual report shows strong approval numbers for human and veterinary medicines
Open originalChronological source-dated updates from public sources on AI medicine, biotechnology, drug discovery, clinical trials, genomics, longevity, biomedical research, and AI-for-science.

EMA’s 2025 annual report shows strong approval numbers for human and veterinary medicines
Open original
HHS, responding to China’s rise, moves to fast-track early drug research
Open original
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 June 2026
Open original

width="27" alt=""/> Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
Open original
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial
Open original
→ Leveraging the Power of Patient Data in AI-Drug Discovery
Open original
MIT researchers’ approach captures subtle atomic patterns, improving predictions of material properties.
Open original
Note: Press announcements from 2004-2012 , 2013-2016 , 2017 , 2018-2020 , 2021 , 2022 , and 2023 are available through the FDA.gov Archive. Some links in press announcements may no longer be active. For more information, contact FDA’s Office of Media Affairs…
Open original
Securing internal systems with an AI Control Roadmap, combining traditional safeguards and real-time monitoring.
Open original